ClinConnect ClinConnect Logo
Search / Trial NCT01477957

The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism

Launched by GERMAN DIABETES CENTER · Nov 22, 2011

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

Weight Loss After Bariatric Surgery Insulin Sensitivity Insulin Resistance

ClinConnect Summary

This clinical trial is looking at how bariatric surgery, a weight-loss surgery, can improve insulin sensitivity and energy usage in people with obesity and type 2 diabetes. The study aims to understand if the surgery can help reduce the fat stored in the liver and how that might connect to inflammation in the liver. Essentially, researchers want to see if surgery can help people better manage their blood sugar and improve their overall energy metabolism.

To participate in this trial, you need to be between 20 and 70 years old and have a body mass index (BMI) that falls into normal weight or obesity categories. This includes individuals with a BMI of 20-25 (normal weight), 35-39.9 (obesity grade 2), or over 40 (obesity grade 3). If you qualify and decide to join, you can expect to undergo assessments related to your insulin sensitivity and energy metabolism. However, there are some medical conditions and recent health issues that may prevent you from participating, such as heart disease, liver disease, or active infections. This trial is currently recruiting participants, and it offers a chance to contribute to important research that could help improve treatment options for obesity and diabetes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged ≥ 20 years- ≤ 70 years
  • BMI 20- 25 kg/m 2 normal- weight group
  • BMI 35- 39,9 kg/m 2 (Obesity grade 2)
  • BMI \>40 kg/m 2 (Obesity grade 3)
  • Exclusion Criteria:
  • Acute illness 2 weeks before start of examination
  • Autoimmune or Immune disorder diseases (Leukozyten \< 5000/µl
  • Renal insufficiency (Kreatin \> 1,5 mg/dl)
  • Heart disease, condition after heart attack
  • Anemia (Hb \<12g/l, controlled before every day of examination) or blood donations 4weeks before examination.
  • Participation in another trial within the last 2 weeks
  • Pharmacological- immunotherapy (Cortisol, Antihistaminika, ASS)
  • Thyroid disorders
  • Glitazone Therapy
  • Pregnancy, Lactation, Menstruation
  • Smoking cigarettes, Alcohol- and drug abuse
  • Psychiatric disorders
  • Risk for/ or diagnosed HIV/ AIDS or Hepatitis B/C
  • Liver disease, which are not caused by non- alcoholic steato- hepatitis
  • Working on night shifts or irregular rhythm of night- day
  • Impaired wound healing or clotting disorders
  • Allergic reaction to local anesthetics
  • Malignant cancer

About German Diabetes Center

The German Diabetes Center (Deutsches Diabetes-Zentrum, DDZ) is a leading research institution dedicated to advancing the understanding, prevention, and treatment of diabetes and its related complications. As a prominent sponsor of clinical trials, the DDZ integrates cutting-edge scientific research with clinical practice, focusing on innovative therapeutic strategies and patient-centered care. With a commitment to excellence, the center collaborates with national and international partners to facilitate groundbreaking studies that aim to improve health outcomes for individuals affected by diabetes. Through its robust infrastructure and expertise, the German Diabetes Center plays a crucial role in shaping the future of diabetes research and management.

Locations

Düsseldorf, Nrw, Germany

Düsseldorf, Nrw, Germany

Patients applied

AW

WT

2 patients applied

Trial Officials

Michael Roden, Prof., MD

Principal Investigator

German Diabetes Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials